Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily engaged in the development and commercialization of groundbreaking treatments for cystic fibrosis. Its existing portfolio includes therapies such as SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, prescribed for individuals with cystic fibrosis who exhibit particular mutations in their cystic fibrosis transmembrane conductance regulator gene. Additionally, TRIKAFTA is available for CF patients aged six and older possessing at least one F508del mutation. Beyond CF, Vertex maintains a robust development pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin deficiency; VX-147, also in Phase 2, targeting APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other significant renal conditions; VX-880, a Type 1 Diabetes treatment undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor for acute, neuropathic, and musculoskeletal pain, in Phase 2; and CTX001, a Phase 3 candidate for severe sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT). The company distributes its products through specialty pharmacies and distributors within the United States, and globally via specialty distributors, retail chains, hospitals, and clinics. Vertex actively collaborates with numerous entities including Affinia Therapeutics, Inc., Arbor Biotechnologies, Inc., CRISPR Therapeutics AG., Kymera Therapeutics, Inc., Mammoth Biosciences, Inc., Moderna, Inc., Obsidian Therapeutics, Inc., Skyhawk Therapeutics, Inc., Ribometrix, Inc., Genomics plc, Merck KGaA, Darmstadt, Germany, and X-Chem, Inc. Founded in 1989, Vertex Pharmaceuticals Incorporated is headquartered in Boston, Massachusetts.